Board Meeting5 May 2026, 02:07 pm

Emcure Pharma: Board approves FY26 Audited Results, ₹3.60 Dividend

AI Summary

Emcure Pharmaceuticals Ltd's Board of Directors approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The board recommended a final dividend of ₹3.60 per equity share (36%) subject to shareholder approval. Additionally, Dr. Mukund Gurjar was re-appointed as a Whole-time Director for one year starting August 28, 2026, and Mr. Satish Mehta was re-appointed as Managing Director for five years commencing April 1, 2027, both subject to member approval.

Key Highlights

Audited financial results for FY26 approved with unmodified audit opinion.
Final dividend of ₹3.60 per share (36%) recommended, pending shareholder approval.
Dr. Mukund Gurjar re-appointed as Whole-time Director for one year.
Mr. Satish Mehta re-appointed as Managing Director for five years.

View BSE Filing

EMCURE

Pharmaceuticals

Emcure Pharmaceuticals Ltd

Price Impact